BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Piga M, Chessa E, Morand EF, Ugarte-gil MF, Tektonidou M, van Vollenhoven R, Petri M, Arnaud L, Appenzeller S, Aranow C, Askanase A, Avcin T, Bae S, Bertsias G, Bonfa E, Cairoli E, Cardiel MH, Cervera R, Chasset F, Chizzolini C, Clarke AE, Conti F, Costedoat-chalumeau N, Czirják L, Doria A, Dörner T, Espinosa G, Fischer-betz R, Garcìa M, Gladman DD, González LA, Gunnarsson I, Hamijoyo L, Hanly JG, Hasni SA, Houssiau FA, Inanç M, Inês LS, Isenberg D, Jacobsen S, Jan Wu Y, Kaneko Y, Katsumata Y, Lau CS, Legge AC, Lerang K, Limper M, Louthrenoo W, Luo S, Marinho A, Massardo L, Mathian A, Mosca M, Nikpour M, Pego-reigosa JM, Peschken CA, Pons-estel BA, Pons-estel GJ, Rahman A, Rednic S, Ribi C, Ruiz-irastorza G, Sato EI, Saxena A, Schneider M, Sebastiani GD, Strand V, Svenungsson E, Tanaka Y, Tazi Mezalek Z, Tee ML, Tincani A, Touma Z, Troldborg A, Vasconcelos C, Vinet É, Vital EM, Voskuyl AE, Voss A, Wallace D, Ward M, Zamora LD. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. The Lancet Rheumatology 2022;4:e441-9. [DOI: 10.1016/s2665-9913(22)00107-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Gioti O, Chavatza K, Nikoloudaki M, Katechis S, Bertsias G, Boumpas DT, Fanouriakis A. Residual disease activity and treatment intensification in systemic lupus erythematosus: A cross-sectional study to quantify the need for new therapies. Lupus 2022;:9612033221129776. [PMID: 36169280 DOI: 10.1177/09612033221129776] [Reference Citation Analysis]
2 Zen M, Gatto M, Doria A. Defining the targets in SLE management: insights and unmet gaps. Ann Rheum Dis 2022:ard-2022-222991. [PMID: 36008131 DOI: 10.1136/ard-2022-222991] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ugarte-Gil MF, Hanly J, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Pons-Estel BA, Alarcón GS. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis 2022:annrheumdis-2022-222487. [PMID: 35944946 DOI: 10.1136/ard-2022-222487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Samões B, Zen M, Abelha-Aleixo J, Gatto M, Doria A. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus. Autoimmun Rev 2022;21:103165. [PMID: 35931316 DOI: 10.1016/j.autrev.2022.103165] [Reference Citation Analysis]